{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:54Z","timestamp":1790630394308,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105271","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:28:18Z","timestamp":1773250098000},"page":"105271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advances in intravesical therapy for non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"Yanfeng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105271_bib3","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic Mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur. Urol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"issue":"3, Supplement","key":"10.1016\/j.critrevonc.2026.105271_bib7","first-page":"48","article-title":"Utility of rescue bacillus calmette-guerin therapy in treatment of BCG-unresponsive non-muscle-invasive bladder cancer","volume":"43","author":"Bai","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib12","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.hoc.2021.02.003","article-title":"Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer","volume":"35","author":"Bree","year":"2021","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single arm phase I\/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus calmette guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105271_bib18","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10516","key":"10.1016\/j.critrevonc.2026.105271_bib19","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus calmette-guerin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib22","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471942","article-title":"New treatment options for non-muscle-invasive bladder cancer","volume":"45","author":"Filon","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib25","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus calmette-guerin therapy","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105271_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.01.015","article-title":"Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure","author":"Gerald","year":"2025","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MOU.0000000000001232","article-title":"Novel intravesical therapies and delivery systems for the management of bladder cancer","volume":"35","author":"Grobet-Jeandin","year":"2025","journal-title":"Curr. Opin. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105271_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"3, Supplement","key":"10.1016\/j.critrevonc.2026.105271_bib31","first-page":"84","article-title":"Outcomes of patients treated with additional BCG following a BCG unresponsive non-muscle-invasive bladder cancer diagnosis","volume":"43","author":"Guske","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib34","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105271_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.01.009","article-title":"Bacillus calmette-guerin plus mitomycin versus bacillus calmette-guerin alone for bacillus calmette-guerin-naive non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP 1301)","author":"Hayne","year":"2026","journal-title":"Eur. Urol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105271_bib36","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hernandez","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"issue":"1B","key":"10.1016\/j.critrevonc.2026.105271_bib38","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/bco2.28","article-title":"Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study","volume":"1","author":"Hurle","year":"2020","journal-title":"BJUI Compass"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.09.017","article-title":"Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure","volume":"39","author":"Hurle","year":"2021","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille calmette-guerin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur. Urol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int. J. Hyperth."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur. Urol."},{"issue":"10061","key":"10.1016\/j.critrevonc.2026.105271_bib45","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105271_bib46","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2023.6804","article-title":"Response to 2 induction courses of bacillus calmette-guerin therapy among patients with high-risk non-muscle-invasive bladder cancer: 5-year follow-up of a phase 2 clinical trial","volume":"10","author":"Katims","year":"2024","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.euf.2023.05.002","article-title":"Complications after radical cystectomy: a systematic review and meta-analysis of randomized controlled trials with a meta-regression analysis","volume":"9","author":"Katsimperis","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.critrevonc.2026.105271_bib49","doi-asserted-by":"crossref","first-page":"S1134","DOI":"10.1016\/j.annonc.2024.08.2048","volume":"35","author":"Kitamura","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib51","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib55","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105271_bib56","article-title":"Efficacy of disitamab vedotin and immune profiles in high-risk non-muscle-invasive bladder cancer with HER2 overexpression","volume":"6","author":"Liu","year":"2025","journal-title":"MedComm (2020)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000002848","article-title":"Sequential intravesical valrubicin and docetaxel for the salvage treatment of non-muscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus calmette-guerin-naive high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib61","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J. Urol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105271_bib62","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to bacillus calmette-guerin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bju.15571","article-title":"Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial","volume":"129","author":"Miyata","year":"2022","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib67","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.716","article-title":"Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer","author":"Moyer","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.eururo.2024.05.027","article-title":"Challenging the paradigm of \"BCG-unresponsive\" bladder cancer: does additional bacillus calmette-guerin have an effect?","volume":"86","author":"Myers","year":"2024","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-guerin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib70","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.111","article-title":"LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib71","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.eururo.2020.05.021","article-title":"Goldilocks and the BCG: bacillus calmette-guerin dose reduction in the age of shortage","volume":"78","author":"Nikas","year":"2020","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib73","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105271_bib74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib75","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0022-5347(17)39174-7","article-title":"Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder","volume":"142","author":"Pan","year":"1989","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus calmette-guerin-naive nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial","volume":"21","author":"Perdona","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur. Urol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105271_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 +\/- transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib82","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \"BCG failure\" non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A phase 1\/2 single-arm clinical trial of recombinant bacillus calmette-guerin (BCG) VPM1002BC immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur. Urol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105271_bib86","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus calmette-guerin therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib88","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib89","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2026.105271_bib90","doi-asserted-by":"crossref","unstructured":"Shen, Y., Peng, L., Gu, W., Lu, X., Shen, Y., & Ye, D. (2025). Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study. In: American Society of Clinical Oncology.","DOI":"10.1016\/j.eururo.2025.09.3980"},{"key":"10.1016\/j.critrevonc.2026.105271_bib91","article-title":"PD03-02 Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J. Urol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105271_bib92","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib93","doi-asserted-by":"crossref","unstructured":"Shore, N.D., Nishiyama, H., Shariat, S.F., Steinberg, G., Kamat, A.M., Alanee, S.R., Nam, K., Imai, K., Kapadia, E., & Hahn, N.M. (2024). Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Gu\u00e9rin (BCG) with or without pembrolizumab for high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC) that persists\/recurs after BCG induction. In: American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS722"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105271_bib94","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib95","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib97","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J. Urol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105271_bib98","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib99","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105271_bib100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105271_bib101","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105271_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","article-title":"Bladder-sparing treatment in patients with bacillus calmette-guerin-unresponsive non-muscle-invasive bladder cancer: an analysis of long-term survival outcomes","volume":"53","author":"Tan","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105271_bib104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105271_bib105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.3693","article-title":"3079P Efficacy and safety results from Formula-01: a phrase II study of Disitamab Vedotin plus BCG in HER2 high expression high-risk non-muscle invasive bladder cancer patients (HR-NMIBC)","volume":"36","author":"Tan","year":"2025","journal-title":"Ann. Oncol."},{"issue":"5S2","key":"10.1016\/j.critrevonc.2026.105271_bib107","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","article-title":"P2-02 pivotal results from BOND-003: A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"211","author":"Tyson","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105271_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105271_bib109","article-title":"PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105271_bib110","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:45:00Z","timestamp":1778481900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":110,"alternative-id":["S1040842826001587"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105271","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in intravesical therapy for non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105271"}}